GDF15 and metabolic dysfunction-associated steatotic liver disease: The negative regulation of circulating GDF15 during weight loss therapy is of particular interest, due to its regulatory role in nutritional behavior and potential implications for obesity therapy [31], as well as its association with NAFLD [23].